Login to Your Account



Cornerstone Mulls Next Steps for Lixivaptan After CRL

By Marie Powers
Staff Writer

Thursday, November 1, 2012
regulatory.jpg

With government offices still hampered by the cleanup from Hurricane Sandy, the FDA was several days late responding to Cornerstone Therapeutics Inc.'s new drug application for lixivaptan. The decision, reported Thursday, was no shocker.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription